SCHEDULE: CytoMed Chairman Boosts Stake to 22.05%

CytoMed Therapeutics Limited's Chairman, Choo Chee Kong, has increased his beneficial ownership to 22.05% of the company's ordinary shares.

Summary

• Choo Chee Kong, Chairman and Director of CytoMed Therapeutics Limited, beneficially owns 2,587,746 Ordinary Shares.
• This ownership represents 22.05% of the Issuer's 11,733,912 outstanding shares.
• Ownership includes 2,075,310 shares held indirectly through Glorious Finance Limited (where Mr. Choo owns a 55% stake), 194,112 shares held by EP Capital Inc., and 318,324 shares held directly.
• Shares were acquired through capital contributions to the Issuer and public open market purchases using personal funds.
• Between October 2, 2025, and October 28, 2025, Mr. Choo purchased an aggregate of 130,824 ordinary shares in open market transactions.
• The Reporting Person has sole voting and dispositive power over 512,436 Ordinary Shares and shared voting and dispositive power over 3,773,291 Ordinary Shares.
• The Reporting Person and other shareholders of Glorious Finance Limited may be deemed a 'group' under Section 13(d)(3) due to shared voting and dispositive power over 3,773,291 shares, though no formal agreement exists.

Sentiment

Score: 7

Explanation: The increased stake by the Chairman, including recent open market purchases, suggests a positive sentiment from insider management regarding the company's value and future prospects. While it's a routine filing, the nature of the transaction is generally viewed favorably by investors.

Positives

• Increased insider ownership by the Chairman may signal confidence in the company's future prospects.
• Open market purchases demonstrate a direct financial commitment from a key executive.

Risks

• The potential classification of Mr. Choo and other Glorious Finance Limited shareholders as a 'group' could imply coordinated actions, even without a formal agreement, which might influence corporate control dynamics.

Future Outlook

The filing indicates Mr. Choo Chee Kong's continued investment interest in CytoMed Therapeutics Limited, primarily for investment purposes. As Chairman and a Director, he may participate in discussions and votes on strategic matters, but no specific future plans or proposals are outlined beyond his investment intent.

Management Comments

• Mr. Choo Chee Kong has acquired all of the Ordinary Shares beneficially owned by him for investment purposes.
• The Reporting Person serves as Chairman of the Issuer and is a member of the board of directors of the Issuer and, as a result, may be asked to vote on or discuss matters related to items (a) through (j) of this Item 4 of Schedule 13D with representatives of the Issuer and others.

Industry Context

NA

Corporate Governance

Related Party Transactions

• Mr. Choo Chee Kong holds 55% stake in Glorious Finance Limited, which indirectly holds 2,075,310 Ordinary Shares of CytoMed Therapeutics Limited. This represents a significant indirect holding through a related entity.

Stakeholder Impact

• Shareholders: Increased insider ownership may be perceived positively, signaling management confidence and alignment of interests.
• Management: The Chairman's increased stake reinforces his commitment and influence within the company.

Next Steps

• Mr. Choo Chee Kong will continue to serve as Chairman and Director, potentially influencing strategic decisions.
• Further Schedule 13D amendments would be filed if there are material changes to his beneficial ownership or investment intent.

Key Dates

Recommendation

The filing indicates a significant insider purchase by the Chairman, which is generally a positive signal of confidence. However, as a Schedule 13D, it primarily reports ownership changes rather than operational or financial performance. While the insider buying is a good sign, it's not sufficient on its own to warrant a 'buy' recommendation without further analysis of the company's fundamentals, financial health, and strategic outlook. It reinforces a 'hold' position for existing investors and suggests potential for further due diligence for prospective investors.

Keywords

CytoMed Therapeutics, Choo Chee Kong, Schedule 13D, Beneficial Ownership, Insider Buying, Shareholder Stake, Biotechnology, Singapore, Corporate Governance